BioCryst Pharmaceuticals (BCRX)

	SUMMARY

	BULLS

	BEARS

	TOPICS

	DATA CENTRAL

	STOCK CHART

	SEC FILINGS

	BALANCE

	INCOME

	CASH FLOW

Annual Reports

Quarterly Reports

8-K

8-K (Jan 8, 2013)8-K (Jan 4, 2013)8-K (Dec 7, 2012)8-K (Nov 30, 2012)8-K (Nov 27, 2012)8-K (Nov 8, 2012)8-K (Nov 1, 2012)8-K (Oct 31, 2012)8-K (Oct 22, 2012)8-K (Oct 18, 2012)8-K (Aug 2, 2012)8-K (Jul 24, 2012)8-K (Jul 9, 2012)8-K (May 25, 2012)8-K (May 7, 2012)8-K (May 3, 2012)8-K (Mar 12, 2012)8-K (Feb 16, 2012)8-K (Jan 20, 2012)8-K (Nov 18, 2011)8-K (Nov 14, 2011)8-K (Nov 2, 2011)8-K (Oct 11, 2011)8-K (Oct 5, 2011)8-K (Aug 4, 2011)8-K (Jul 1, 2011)8-K (Jun 27, 2011)8-K (May 25, 2011)8-K (May 17, 2011)8-K (May 4, 2011)8-K (May 3, 2011)8-K (Feb 24, 2011)8-K (Feb 18, 2011)8-K (Feb 10, 2011)8-K (Jan 21, 2011)8-K (Jan 12, 2011)8-K (Oct 28, 2010)8-K (Aug 5, 2010)8-K (May 18, 2010)8-K (May 7, 2010)8-K (Apr 28, 2010)8-K (Feb 4, 2010)8-K (Dec 10, 2009)8-K (Nov 24, 2009)8-K (Oct 29, 2009)8-K (Oct 28, 2009)8-K (Sep 23, 2009)8-K (Jul 30, 2009)8-K (May 8, 2009)8-K (Feb 6, 2009)8-K (Jan 28, 2009)8-K (Dec 29, 2008)8-K (Nov 10, 2008)8-K (Nov 4, 2008)8-K (Oct 31, 2008)8-K (Oct 24, 2008)8-K (Aug 7, 2008)8-K (Jul 28, 2008)8-K (Jul 10, 2008)8-K (Jun 18, 2008)8-K (May 28, 2008)8-K (May 21, 2008)8-K (May 8, 2008)8-K (Mar 4, 2008)8-K (Jan 10, 2008)8-K (Nov 13, 2007)8-K (Nov 8, 2007)8-K (Sep 19, 2007)8-K (Sep 17, 2007)8-K (Aug 29, 2007)8-K (Aug 10, 2007)8-K (Aug 9, 2007)8-K (Aug 7, 2007)8-K (Aug 6, 2007)8-K (Jul 26, 2007)8-K (Jul 24, 2007)8-K (Jul 18, 2007)8-K (May 9, 2007)8-K (Mar 27, 2007)8-K (Mar 6, 2007)8-K (Feb 7, 2007)8-K (Jan 11, 2007)8-K (Dec 22, 2006)8-K (Nov 8, 2006)8-K (Oct 20, 2006)8-K (Sep 20, 2006)8-K (Aug 9, 2006)8-K (May 2, 2006)8-K (Apr 27, 2006)8-K (Feb 8, 2006)8-K (Feb 2, 2006)8-K (Jan 17, 2006)8-K (Dec 22, 2005)8-K (Dec 21, 2005)8-K (Dec 16, 2005)8-K (Dec 13, 2005)8-K (Dec 12, 2005)8-K (Nov 30, 2005)8-K (Oct 26, 2005)8-K (Oct 6, 2005)8-K (Aug 31, 2005)8-K (Aug 9, 2005)8-K (Aug 3, 2005)8-K (Jul 1, 2005)8-K (Jun 20, 2005)8-K (May 10, 2005)8-K (Apr 21, 2005)8-K (Mar 21, 2005)8-K (Mar 15, 2005)8-K (Mar 9, 2005)8-K (Feb 17, 2005)8-K (Feb 7, 2005)8-K (Feb 2, 2005)8-K (Dec 7, 2004)8-K (Nov 8, 2004)8-K (Oct 20, 2004)8-K (Oct 19, 2004)8-K (Jul 21, 2004)8-K (Apr 21, 2004)8-K (Mar 31, 2004)8-K (Feb 17, 2004)8-K (Feb 4, 2004)8-K (Dec 16, 2003)8-K (Oct 20, 2003)8-K (Jul 30, 2003)8-K (Apr 23, 2003)8-K (Jun 17, 2002)8-K (May 1, 2001)8-K (Aug 2, 1996)8-K (Jun 25, 1996)

Other

BioCryst Pharmaceuticals 8-K 2005

Documents found in this filing:

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report: July 1, 2005

BioCryst Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)

Delaware		000-23186		62-1413174
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification #)

2190 Parkway Lake Drive, Birmingham, Alabama 35244
(Address of Principal Executive Office)

(205) 444-4600
(Registrant’s telephone number, including area code)

Item 8.01 Other Events.

BioCryst is providing an update on the status of its influenza neuraminidase inhibitor, peramivir. BioCryst possesses exclusive rights to peramivir and maintains the patents covering the compound. BioCryst announced in June 2002 it was discontinuing development of peramivir following a Phase III clinical trial that yielded results that were not statistically significant. Given international health concerns regarding avian flu, the Company has explored possible additional development of the drug candidate. Peramivir has shown activity against avian (bird) flu in cell culture and in animals in pre-clinical testing. The Company is considering various options for the development of peramivir, including whether to file an Investigational New Drug (IND) application with the U.S. Food and Drug Administration to conduct clinical trials in humans for avian and other viral strains of influenza. BioCryst intends to announce when appropriate its decision on possible future development of peramivir.

Neither the filing of this Current Report on Form 8-K nor the inclusion in such 8-K of a reference to Registrant’s Internet address shall, under any circumstances, be deemed to incorporate the information available at such Internet address into this Current Report on Form 8-K. The information available at Registrant’s Internet address is not part of this Current Report on Form 8-K or any other report filed by Registrant with the Securities and Exchange Commission.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: July 1, 2005	BIOCRYST PHARMACEUTICALS, INC.

	By:	/s/ MICHAEL A. DARWIN

		Michael A. Darwin
		Chief Financial Officer and Chief
		Accounting Officer

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.

Mobile | Advertise | Licensing & Partnerships | Blogger Tools | Jobs

BioCryst Pharmaceuticals (BCRX)

Annual Reports

Quarterly Reports

8-K

Other

Documents found in this filing: